Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Exelixis  (Stock symbol: EXEL )

1851 Harbor Bay Parkway
Alameda, CA 94502
USA
(650)-837-7000
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) Carl B Feldbaum (Biotechnology Industry Organization President) Jacqueline Wright (Microsoft Chief Digital Officer) Alan M Garber (Stanford University Professor) George Scangos (Exelixis Director) Vincent Marchesi (Yale University Professor) Frank McCormick (Onyx Pharmaceuticals Former Chief Scientific Officer) Stelios Papadoupoulos (SG Cowen Former Vice Chairman) George Poste (SmithKlineBeecham Former Chief Science & Technology Officer, President of R&D) Lance Willsey (DCF Capital Founding Partner) Jack L Wyszomierski (Schering-Plough Former CFO)
Former outside board: Charles M Cohen (Cellzome GmbH Former CEO) Jason Fisherman (Advent International);  Jean-Francois Formela (Accomplice{1});  Peter Stadler (Artemis Pharmaceuticals GmbH)
Company

Business description: Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery - all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer
Customers include: Bayer;  Wyeth Pharmaceuticals
Partners include: Bristol-Myers Squibb CytokineticsGlaxoSmithKlineMerckPDL BioPharmaScios;  Bayer CropScience;  Dow Agrosciences ;  Renessen LLC;  Schering-Plough Research Institute
Capital

Rounds: 4
Recent Fundings: Jul 1999   Dec 1997
Capital raised: 46.8M
Last Round: 4.0M
Ownership: Public  
Stock Symbol: EXEL
Angels/other VCs: Carl Cohen (CreativBio);  Lance Willsey
Corporate investors: Pharmacia;  Sete

Last Tweets


 

Last Mentions


Overview
Record updated: Jan 2022
Sector: Biotech
Year Founded: 1994
Headcount: 1001-1250 as of Jan 2022
Rounds: 4
Recent Fundings: Jul 1999   Dec 1997
Capital Raised: 46.8M
Last Round: 4.0M
Ownership: Public  
Stock Symbol: EXEL